Makers Laboratories Limited

MAKERSL6

INE987A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:57 2024-06-28 am EDT			5-day change	1st Jan Change
129 ^INR	-1.60%		-6.83%	-6.93%

May. 23	Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories	MT
May. 23	Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company Secretary

October 31, 2022 at 03:46 am EDT

Makers Laboratories Limited informed that Ms. Rinku Kholakiya, Company Secretary has resigned from the services of the Company with effect from close of business hours on 31st October, 2022 and accordingly, she will cease to be the Company Secretary and Key Managerial Personnel of the company from 1st November, 2022.

Latest news about Makers Laboratories Limited

Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories	May. 23	MT
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 23	CI
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 23	CI
Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024	Feb. 15	CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Makers Laboratories Gets Eurasian Economic Union RU GMP Certificate for Ophthalmic Eye Drops Manufacturing Plant	23-10-05	MT
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-22	CI
Makers Laboratories Limited Appoints Surbhi Sharma as Company Secretary and Compliance Officer	23-04-28	CI
CARE Affirms BBB+ Rating on Makers Laboratories' Bank Financing; Outlook Stable	23-03-08	MT
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company Secretary	22-10-31	CI
Makers Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-07-15	CI
Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance Officer	22-02-09	CI
Makers Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-09	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-10	CI
Makers Laboratories : Swings to Loss in Fiscal Q4	21-06-11	MT
Makers Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-10	CI
Makers Laboratories : CARE Reaffirms BBB+ Rating on Makers Laboratories' Bank Facilities; Outlook Stable	21-03-22	MT
Makers Laboratories Limited completed the acquisition of 0.002% stake in Resonance Specialties Limited for INR 0.01 million.	20-12-09	CI
Makers Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-04	CI
Makers Laboratories Limited made an offer to acquire 26% stake in Resonance Specialties Limited for approximately 170 million.	20-09-28	CI

Chart Makers Laboratories Limited

Duration

Period

More charts

Company Profile

Makers Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceuticals. The Company operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-emetics and anti-thyroid, cough & cold control, digestives, neurotronic, nutritional supplements, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAKERS LABORATORIES LIMITED	-6.93%	9.13M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.82%	14.34B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B